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lowed up to review the management of adverse event(s). Results: A total of 226 
radiation related adverse events were found during study period. Among the study 
subjects, majority of them received chemo-radiation (n= 126: 56%) than radiother-
apy (n= 100: 44%) alone. Majority of events observed were Fatigue (n= 39: 17.2%), fol-
lowed by Mucositis (n= 29: 12.8%), Pain (n= 23: 10.17%), Diarrhea (n= 23: 10.17%) and 
Gastritis (n= 22: 9.7%). Less common events were Proctalgia (n= 20:8.8%), Vomiting 
(n= 18: 7.9%), Burning micturition (n= 7: 3%), Dermatitis (n= 7:3%) and Pyrexia (n= 6: 
2.6%). Majority of the vomiting (55%), dehydration (80%), proctalgia (65%), pyrexia 
(67%) and burning micturition (57%) were categorized as grade 1 and grade 2. 
Grade 3 and 4 events were observed as vomiting (17%), diarrhea (13%), fatigue (5%), 
gastritis (4.5%), proctalgia (5%) and mucositis (14%). Most of the grade 3 events or 
grade 4 events were reported in patients who received external radiation therapy 
and was on chemo-radiation therapy compare to who received other types of 
radiation therapy and was on radiation therapy alone. ConClusions: Adverse 
events were found more in patients who received external radiation therapy than 
other types of radiation therapy. Patients on radiation and chemo radiation therapy 
need to be carefully followed up to identify radiation related negative outcomes. 
Appropriate follow up and management of these events reduces patients’ burden 
of cure .
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objeCtives: First-line EGFR-TKIs has become established in EGFR mutation–posi-
tive NSCLC. According to large scale meta-analysis, erlotinib and afatinib showed a 
non-significant difference in efficacy; however, the incidence and severity of EGFR-
TKI–related adverse events (AE) was lower with erlotinib. These safety differences 
may be related to the mechanisms of action (e.g. reversible versus irreversible inhibi-
tion). This study aims to compare the AE costs associated with both drugs, from the 
perspective of the Spanish National Health System (NHS). Methods: The frequency 
of AE was obtained from a recently published meta-analysis using log-linear mixed-
effects models. In Spain, the daily cost of both treatments is the same, therefore, 
only the AE costs were considered. The resources use in the AE management were 
estimated by a Spanish oncologist’s panel and from previous studies conducted 
in Spain. Monte-Carlo simulation was chosen as it allows simulating the effect of 
changes in different parameters obtained from clinical studies and other sources 
to describe real-life distributions. Parameters used in the simulation were the AE 
rates and AE management costs. Results: 1,000 model iterations were generated. 
The AE total cost per patient treated with erlotinib and afatinib was € 657.44 and 
€ 1,272.15, respectively. With erlotinib, the cost per patient due to AE grade ≤ 2 and 
≥ 3 was € 550.86 and € 106.58, respectively, and the cost with afatinib was € 980.63 and 
€ 291.52, respectively too. The reduction in the number of AE with erlotinib could lead 
to average health care costs avoided to the NHS of € 614.71 (95%CI € 324.57; € 881.29) 
per patient. ConClusions: In EGFR mutation-positive NSCLC, first-line erlotinib 
could reduce the health care costs for the Spanish NHS due to the decreased rate 
of AE compared with afatinib. For long-term therapies, avoiding complications and 
reducing costs in the AE management are relevant factors to facilitate the sustain-
ability of health care systems.
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objeCtives: Adverse drug reactions (ADRs) are contributing to poor medication 
adherence, delayed treatment, poor quality of life and increased treatment cost 
in cancer patients. This study was conducted to detect and monitor adverse drug 
reactions (ADRs) through spontaneous reporting and contineous monitoring system 
in patients receiving cancer chemotherapy. Methods: A prospective study was 
conducted at specialty cancer hospital for a period of six months. Clinical pharma-
cists followed the patients admitted to different wards of a study hospital. Medical 
records of the patients were reviewed and patients and their care givers were inter-
viewed to identify ADR. Identified ADRs were discussed with concerned oncologists, 
documented electronically and assessed further. Results: A total of 456 ADRs were 
reported in 378 patients from 410 patients followed during 6 months of period. 
Vomiting (n= 124, 25.87%), blood and bone marrow toxicities (n= 89, 19.51%), con-
stipation (7.8%), alopecia (7%), diarrohea (6.14%), myalgia (4.82%) and peripheral 
neuropathies (4.82%) were common ADRs reported. Anaphylaxis (3.5%), hyperpig-
mentation (3.2%) opportunistic infections (2.63%), muscle cramps (2.4%), hands foot 
syndrome (1.7%), acute renal failure, vasospasm and cardiac toxicities (less than 1%) 
were found less commonly. Cisplatin (27%), Paclitaxel (14.9%), Cyclophosphamide 
(7%), Doxorubicin (4.82%), Fluorouracil (3.9%), Carboplatin (3.28%), Gemcetabine 
(3.07%), Rituximab (1.97%) were drugs found to be associated with ADRs. Most 
(87%) of the ADRs did not lead to cessation of drug but 4% of them needed dosage 
alternation.104 of 124 cases of vomiting were attributed to inappropriate frequency 
and regimen of anti-emetics. 32 of 89 cases of blood injuries were found due to 
lack of preventive care and 16 of 89 cases of blood injuries were suspected due to 
inappropriate dosing. 13 of 16 cases of anaphylaxis were reported due to use of 
specific brand product of Paclitaxel. ConClusions: ADRs due to inappropriate 
frequency, improper dosing and specific formulation can be prevented by imple-
menting quality drug distribution system and strict prescribing and monitoring 
policies.
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objeCtives: The safety and effectiveness of Selective Retina Therapy as a procedure 
that induces the regeneration of the retinal pigmented epithelial cells by selectively 
destroying only the retinal pigmented epithelial cell in patients with retinal diseases 
were assessed. Methods: Assessment was made on the Selective Retina Therapy 
by extending the range of patients to be subjected to this technology by includ-
ing macular edema and central serous chorioretinopathy patients. Intervention 
procedures included a broad range of technologies that selectively damages the 
retinal pigments and all devices without limitation were selected in assessment of 
the safety and effectiveness of this technology. For information search, 8 domestic 
databases including Korea Med and overseas databases including Ovid-Medline, 
Ovid-Embase and Cochrane Library were used. A total of 55 relevant literatures were 
searched through the use of search words related to ‘selective retina therapy’. As 
the result, a total of 7 literatures were included in the final assessment by applying 
the criteria for selection and exclusion to the 28 literatures after having excluded 27 
overlappingly searched literatures. Each of the stages from literature search to appli-
cation of selection standards and extraction of data were carried out independently 
by 2 assessors under the deliberation by the Sub-committee. Results: Although 
there is no safety problem with the Selective Retina Therapy when implemented 
on central serous chorioretinopathy patient, there is no literature that made report 
on the key effectiveness variable of the Therapy,making the assessment of the 
effectiveness of this technology difficulty. ConClusions: Therefore, this technol-
ogy was assessed to be at a stage that requires further researches (Recommendation 
rating of D, Classification as technology in research stage i).
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objeCtives: Biologic therapies are approved for moderate/severe plaque psoria-
sis. In trials of newer biologics, many patients achieved complete skin clearance. 
This abstract reports interim Resultsfrom a study examining real-world effective-
ness of biologics in psoriasis. Methods: This prospective observational study 
includes adults initiating biologic treatment, or switching to a new biologic, for 
psoriasis in Europe and the US. Dermatologist evaluation of the Psoriasis Area and 
Severity Index (PASI) and the patient-reported Psoriasis Symptom Index (PSI] and 
Dermatology Life Quality Index (DLQI) are collected at baseline, 6 and 12 months 
after biologic initiation. Endpoints include complete skin clearance (100% improve-
ment in PASI [PASI 100] or PASI= 0), PASI 90, PASI 75, PSI and DLQI. Missing data are 
imputed using the last observation carried-forward. These interim Resultsinclude 
patients who had the opportunity to complete a 6-month assessment. Results: 
This interim analysis included 126 patients (69.8% male, mean [SD] age 47.3 [14.3] 
years, mean [SD] psoriasis duration 17.3 [12.9] years). At baseline, mean (SD) PASI 
was 14.8 (9.4), and 53.2% patients were biologic-naïve. At 6-months, 17.5% [95% 
CI: 11.3%, 25.2%] of patients achieved complete skin clearance; fewer than half 
(48.0% [39.0%, 57.1%]) achieved a PASI 75, 28.0% [20.3%, 36.7%] achieved a PASI 90, 
and 17.6% [11.4%, 25.4%] a PASI 100. In addition, 16.8% of patients had a PSI of 0 
and 23.8% a DLQI of 0 (lower scores indicate fewer psoriasis symptoms and better 
quality of life). ConClusions: Fewer than 20% of patients achieved complete 
skin clearance 6 months after initiating a biologic and less than half achieved a 
75% improvement in PASI. In addition, more than 75% of patients reported some 
decrement to quality of life and more than 80% reported psoriasis symptoms. 
These Resultssuggest that more effective treatments could improve outcomes 
for many patients with moderate to severe psoriasis.
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objeCtives: This study was conducted to assess the pattern of radiation related 
adverse events and its management in patients who are on radiation therapy or 
chemo-radiation therapy. Methods: This was a prospective observational study 
conducted for a period of six months. Patients on radiation therapy or chemo-radi-
ation therapy were enrolled and followed by clinical pharmacists on daily basis to 
identify adverse event(s) if any. Upon identification, adverse events were discussed 
with concerned radiation oncologists for authentication and graded as per defined 
by Radiation Therapy Oncology Group (RTOG). Enrolled patients were further fol-
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4.6% -26.2% vs. 3.1% - 12.5%) was better with combination therapy vs. control 
group therapies. In two studies, patients on vandetinib and docetaxel combination 
therapy showed a significant improvement (p< 0·0001) in PFS and overall response 
rate versus those randomly assigned to receive docetaxel only. Results of meta- 
analysis demonstrate that combined targeted therapy has better OS (WMD: 1.23 
[95% CI: 0.06, 2.41], p = 0.04), PFS (WMD: 1.07 [95% CI: 0.7, 1.45], p < 0.00001) and 
ORR (OR: 1.85 [95% CI: 1.49, 2.31], p < 0.00001). The AE profile (gastrointestinal, 
vascular, infectious and blood disorders) was better in the control group thera-
pies. ConClusions: Survival benefit and response rate with combined inhibition 
therapy against EGFR and VEGF was better than the VEGF or EGFR alone inhibi-
tion. Combination therapy was associated with increased toxicity resulting in low 
compliance and dose reduction or discontinuation.
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objeCtives: To assess the association between antidepressants (ADs) use and 
male-only cancers. Methods: Embase and PubMed were searched for relevant 
human studies published in English. Data was extracted for study population, study 
characteristics, interventions, and risk of male cancers (prostate [PC], testicular [TC], 
penile [PNC], and male breast cancer [MBC]). Results: Of the 374 results that were 
obtained from the literature search, five case-control studies (three assessed PC risk 
and two assessed TC risk) and one case-report (assessed MBC risk) met the inclu-
sion criteria. None of the included studies assessed PNC risk. In a population-based 
study, no significant association was found between selective serotonin reuptake 
inhibitors (SSRIs) use and PC (risk ratio [RR]= 1.01 [95% CI: 0.82-1.25]). Similarly, no 
significant association was found between ADs use and PC risk in other two stud-
ies. Significantly positive association was found between tricyclic antidepressants 
(TCAs) use for 2-5 years and PC with a RR of 1.31 (1.14-1.51), 1.58 (1.29-1.93), and 
2.42 (1.87-3.12) for the low, medium, and high average daily dose levels, respectively. 
However, authors acknowledged detection bias as possible reason for the observed 
association. SSRIs were found to be significantly associated with TC (fluoxetine 
RR= 2.51 [1.39-4.53]; paroxetine RR= 2.44 [1.25-4.74]) in one study. A four-year follow-
up study re-tested the association with 12 ADs. In multivariate analyses in this 
study, neither fluoxetine (odds ratio [OR]= 1.22 [0.88-1.71]) nor paroxetine (OR= 1.19 
[0.78-1.83]) or all SSRIs combined (OR= 1.21 [0.92-1.58]) were significantly associ-
ated with TC risk. All TCAs (OR= 1.06 [0.75-1.51]) and all ADs combined (OR= 1.06 
[0.85-1.32]) were also not associated with TC risk. In a report of three cases, authors 
reported an anecdotal association between SSRIs and MBC. ConClusions: The 
results do not indicate significant association between ADs use and risk of male-
only cancers. In most cases, weak positive associations disappeared after adjusting 
for confounding factors.
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objeCtives: To assess the impact that serious post-operative infections (SPOI) 
have on hospitalization outcomes (i.e., resource utilization, length of stay, 
and inpatient mortality) in pediatric patients undergoing brain tumor resec-
tion. Methods: Data from the 2003-2012 Nationwide Inpatient Samples (United 
States Agency for Healthcare Research & Quality) were analyzed for this study. 
Patients aged 20 and younger were eligible for inclusion if they had a malignant 
brain tumor (ICD-9 diagnosis codes 191.xx and/or 198.3) and underwent tumor 
resection (ICD-9 procedure code 01.59) during hospitalization. SPOI, including 
bacteremia (ICD-9 diagnosis code 790.7), septicemia (ICD-9 diagnosis code 038), 
pneumonia (ICD-9 diagnosis codes 481, 482, 483, 485, or 486), and wound infections 
(ICD-9 diagnosis codes 998.51 and/or 998.59) were also identified in the discharge 
summary. The impact of the serious SPOI on hospitalization outcomes were then 
assessed using bivariate and multivariate models. Results: A total of 7,845 pedi-
atric patients underwent brain tumor resection (Median Age: 8 years [IQR: 3-15]. Of 
these patients, 5.9% (N= 461) had a SPOI, of which septicemia/bacteremia was the 
most common (N= 312). SPOIs increased the odds of inpatient death nearly four-
fold (unadjusted OR: 3.76 [2.62-5.40], p< .0001). When adjusted for patient charac-
teristics, SPOIs were still associated with a nearly four-fold increase in the odds 
of inpatient mortality (adjusted OR: 3.73 [2.59-5.36]). Patients with SPOIs stayed 
significantly longer in the hospital (Median: 16 days [IQR: 6-33]) than those with-
out SPOIs (Median: 5 days [IQR: 3-10]) (p< .0001). On average, patients with SPOIs 
underwent four additional procedures during the hospitalization stay (Median: 6 
procedures [IQR: 2-8]) than those without SPOIs (Median: 2 procedures [IQR: 1-5]) 
(p< .0001). ConClusions: SPOIs significantly increase resource utilization, length 
of stay, and odds of inpatient mortality for pediatric patients undergoing brain 
tumor resection. Quality and process improvement efforts should be considered 
to minimize the risk of SPOIs in this patient population.
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objeCtives: Based on the data of the Hungarian Central Statistical Office the preva-
lence of oncological patients in Hungary is growing due to the modern diagnostic 
devices, the effectiveness of diagnostic screening methods and the increasing life 
expectancy. This study aims to assess information about the change in the mortality 
rate in the relevant patient population during the last decades. Methods: This ret-
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objeCtives: Tyrosine kinase inhibitors (TKIs) provide target-specific therapies for 
certain types of malignancies. TKIs may be associated with serious adverse drug 
reactions. We searched the Food and Drug Administration’s Adverse Event Reporting 
System (FAERS) to identify specific adverse drug reactions associated with small 
molecule TKIs in the post-marketing setting. Methods: The TKIs included were 
gefitinib, imatinib, lapatinib, nilotinib, erlotinib, pazopanib, sorafenib, and vande-
tanib. The adverse reactions evaluated were interstitial lung disease (ILD), pneumo-
nitis, pleural effusion, and gastrointestinal hemorrhage, depression, and suicide. 
We searched FAERS for each TKI from their respective approval date and calculated 
empiric Bayesian geometric means (EBGM) to identify significant disproportionality 
signals of each drug and reaction. Results: EBGM for ILD, pneumonitis, and pleu-
ral effusion were significant for gefitinib, imatinib, erlotinib, and sorafenib. EBGM 
for pleural effusion was also significant for nilotinib. The strongest EBGM signals 
were associated with gefitinib/ILD (25.4, n= 320), gefitinib/pneumonitis (10.5, n= 54), 
erlotinib/ILD (7.5, n= 212), nilotinib/pleural effusion (7.0, n= 101), erlotinib/pleural 
effusion (6.9, n= 325), sorafenib/pleural effusion (6.4, n= 70), imatinib/pleural effusion 
(6.3, n= 413), gefitinib/pleural effusion (5.8, n= 118), and erlotinib/pneumonitis (5.7, 
n= 63). EBGM for gastrointestinal bleeding was significant for erlotinib (2.5, n= 156) 
and sorafenib (4.3, n= 63). No significant signals were found for depression or suicide 
with any of the TKIs. Mortality rates for the adverse reactions with significant signals 
were: ILD= 50.8%, gastrointestinal bleeding= 40.6%, pneumonitis= 37.0%, and pleural 
effusion= 31.5%. ConClusions: Serious pulmonary adverse reactions, with high 
rates of mortality, have been reported disproportionately more frequently with gefi-
tinib, imatinib, erlotinib, nilotinib, and sorafenib. Gastrointestinal hemorrhage has 
been reported to FAERS disproportionately more often with erlotinib and sorafenib. 
Limitations of FAERS are that lack of signals among other TKIs may be due to less 
frequent use or reporting of these reactions to FAERS, or shorter post-marketing 
time periods. Physicians and pharmacists should inform and monitor patients on 
TKIs for these reactions.
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objeCtives: Ziv-aflibercept (Ziv) is an anti-angiogenic agent used in combination 
with FOLFIRI (folinic acid, fluorouracil and irinotecan) to treat adults with metastatic 
colorectal cancer (MCC). The purpose of this study is to examine the impact of patient 
characteristics, complications, and comorbidities on treatment patterns and out-
comes of Ziv-treated MCC patients in a real world setting. Methods: A retrospective 
cohort study was conducted on Ziv-FOLFIRI treated MCC patients in the MedAssets 
health system data for inpatient and outpatient visits between January 2012 and April 
2015. Age and gender, hospital characteristics, clinical comorbidities, and utilization 
measures (number of visits, treatment duration, and Ziv initiation) were described. 
Ziv related complications included neutropenia, proteinuria, hypertension, gastroin-
testinal (GI) hemorrhage, and thromboembolism. Multivariate regression models were 
developed to identify drivers of hospital utilization and treatment duration. Results: 
The study population included 337 patients that were predominately male (55.4%) 
with an average age of 58.8 years. The mean Charlson comorbidity score was 7.51. 
Hospital utilization included over 12,000 visits which occurred primarily in the out-
patient setting (96.2%) in teaching facilities (69.0%) with 300 or more beds (87.6%). 
Treatment complications included neutropenia (31.2%), proteinuria (6.2%), hyperten-
sion (48.7%), GI hemorrhage (7.4%), GI perforation (3.2%), and deep vein thrombosis 
(12.2%). Mean treatment duration was 523 days while the average days from colon 
cancer diagnosis to Ziv treatment was 218 days. After adjustments, neutropenia (HR: 
0.771, p= 0.0323) chronic renal disease (HR: 0.649, p= 0.001), and hypertension (HR: 
0.693, p= 0.001) were found to significantly reduce treatment duration. Neutropenia 
(RR: 0.23, p= 0.0135) and sever liver disease (RR: 0.035, p= 0.0008) had a significant 
impact on total visits. ConClusions: Ziv related complications and comorbidities 
can significantly impact treatment viability and ultimately patient survival.
PCN6
effiCACy ANd sAfety Profile of CombiNed tArgeted therAPy  
AgAiNst egfr ANd vegf iN PAtieNts With Previously treAted 
AdvANCed NoN–smAll-Cell luNg CANCer: A systemAtiC revieW ANd 
metA-ANAlysis
Rai MK, Goyal R, Bhutani MK, Kaneria J, Mahendru K, Sharma N
Tata Consultancy Services, Mumbai, India
objeCtives: The objective was to evaluate the clinical efficacy and safety of 
combined targeted therapy against EGFR and VEGF pathways in patients with 
previously treated advanced Non–small-cell lung cancer (NSCLC). Methods: 
Studies were retrieved from Embase, Pubmed and Cochrane databases using 
relevant search strategies. Randomized controlled trials which compared com-
bined targeted therapy with control groups (including single EGFR or VEGF inhi-
bition or/and chemotherapy) were selected as per pre-defined inclusion criteria. 
Outcomes assessed included overall survival (OS), progression free survival (PFS), 
objective response rate (ORR), and adverse events (AEs). Two reviewers indepen-
dently extracted data from the included studies. Data was analysed using RevMan 
(v5.3). Results: Of the 876 studies identified, seven studies with 3347 patients 
were included for meta-analysis. In total, 1688 patients were randomised to com-
bination therapy and 1659 were randomised to control groups. Median OS (range 
8- 13.7 vs. 4.5- 13.4 months), PFS (range 3.4- 4.7 vs. 1.9- 4.8 months) and ORR (range 
